The Relationship Between the Prenatal Exposure to Terbinafine and Abnormal Skin Development in the Newborn Rats

Year 2015, Volume: 10 Issue: 2, 0 - , 20.10.2015

İsmail Can , Hüseyin Serhat İnalöz Serap Sergül İnalöz Necmetin Kırtak Ayhan Eralp Gülname Fındık Güvendi

https://doi.org/10.17094/avbd.39715

Abstract

This study was designed to investigate teratogenic effects of prenatal terbinafine exposure in newborn rats in terms of macroscopic anomalies, anthropometric scales and abnormalities in the skin development. Female Wistar-Albino rats (250–300 g) were randomly divided into control group (physiological saline, during pregnancy; n=6), group A (terbinafine treatment, 20 mg/kg/day, for 21 days; n=6), group B (terbinafine treatment, 20 mg/kg/day, for 51 days; n=6) and group C (terbinafine treatment, 60 mg/kg/day, for 21 days; n=6). After birth, Five rat pups from each experimental group were sacrificed by intracardiac infusion of 10% formalin. Skin biopsies were performed from the abdominal region and prepared for light microscopic analysis. Hyperkeratosis, epidermal atrophy, disordered epidermal cell lineage were demonstrated in all terbinafine doses with increase in severity at higher doses. Damage to hair follicles was observed in group B and C. In conclusion, during pregnancy, terbinafine application time and dose-dependent can cause abnormalities of the skin and growth retardation in newborn rats.

Keywords

Rat, Skin, Teratogenicity, Terbinafine

Exposure to Terbinafine is Associated with Abnormal Skin Development in The Newborn Rats

Abstract

This study was designed to investigate teratogenic effects of prenatal terbinafine exposure in newborn rats in terms of macroscopic anomalies, anthropometric scales and abnormalities in the skin development. Female Wistar-Albino rats (250–300 g) were randomly divided into control group (physiological saline, during pregnancy; n=6), group A (terbinafine treatment, 20 mg/kg/day, for 21 days; n=6), group B (terbinafine treatment, 20 mg/kg/day, for 51 days; n=6) and group C (terbinafine treatment, 60 mg/kg/day, for 21 days; n=6). After birth, Five rat pups from each experimental group were sacrificed by intracardiac infusion of 10% formalin. Skin biopsies were performed from the abdominal region and prepared for light microscopic analysis. Hyperkeratosis, epidermal atrophy, disordered epidermal cell lineage were demonstrated in all terbinafine doses with increase in severity at higher doses. Damage to hair follicles was observed in group B and C. In conclusion, during pregnancy, terbinafine application time and dose-dependent can cause abnormalities of the skin and growth retardation in newborn rats.

Keywords

Deri, Sıçan, Teratojenik, Terbinafin

References

• Bahadir S., Inaloz HS., Alpay K., Agaoglu C., Cimsit G., Parlat P., Tak H., 2000. Continuous terbinafine or pulse itraconazole: A comparative study on onychomycosis. J. Eur. Acad. Dermatol. Venereol., 14, 422-423.
• Bar-Oz B., Moretti ME., Mareels G., VanTittelboom T., Koren G., 1999. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet, 13, 1700-1701.
• Bar-Oz B., Moretti ME., Bishais R., Mareels G., VanTittelboom T., Verspeelt J., Koren G., 2000. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am. J. Obstet. Gynecol., 183, 617-620.
• Begg EJ., 2008. Prescribing in pregnancy and lactation. Brit. J. Clin. Pharmaco., 65(5), 627-628.
• Contini C., Colombo D., Cultrera R., Prini E., Sechi T., Angelici E., Canipari R., 1996. Employment of terbinafine against pneumocystis carinii infection in rat models. Br. J. Dermatol., 46, 30-32.
• Czeizel AE., Metneki J., Kazy Z., Puho E., 2004. A population-based case-control study of oral griseofulvin treatment during pregnancy. Acta. Obstet. Gyn. Scan., 83(9), 827-831.
• De Santis M., Di Gianantonio E., Cesari E., Ambrosini G., Straface G., Clementi M., 2009. First-trimester itraconazole exposure and pregnancy outcome a prospective cohort study of women contacting teratology information services in Italy. Drug Saf., 32(3), 239-244.
• DeVane L., Goetzl LM., Ramamoorthy S., 2011. Exposing fetal drug exposure. Clin. Pharmacol. Ther., 89(6), 786-788.
• Deveci E., Inaloz SS., Inaloz HS., 1998. Teratogenic effects of cadmium on rat skin. Acta. Dermatologica-Kyoto., 93(2), 155-159.
• Fletcher H., Williams NP., Nicholson A., Rainford L., Phillip H., East-Innis A., 2000, Systemic phaeohyphomycosis in pregnancy and the puerperium. West. Indian. Med. J., 49, 79-82.
• Gupta AK., Shear NH., 1997. Terbinafine: an update. J. Am. Acad. Dermatol., 37(6), 979-988.
• Inaloz HS., Ketani MA., Inaloz SS., Yilmaz F., Ketani S., 2000a. The effects of sialoadenectomy and flutamide on skin development. Intl. J. Clin. Exp. Obst. Gynecol., 26, 231-234.
• Inaloz HS., Inaloz SS., Deveci E., Eralp A., 2000b. Teratogenic effects of nicotine on rat skin. Intl. J. Clin. Exp. Obst. Gynecol., 26, 241-243.
• Inaloz HS., Sari I., Inaloz SS., Bayhan G., Unal B., Yayla M., Eralp A., Yuncu M., 2000c. The effects of unilateral uterine artery ligation on skin development. Intl. J. Clin. Exp. Obst. Gynecol., 26, 218-220.
• Katic J., Fucic A., Gamulin M., 2010. Prenatal, early life, and childhood exposure to genotoxicants in the living environment. Arh. Hig. Rada. Toksikol., 61(4), 455-464.
• King CT., Rogers PD., Cleary JD., Chapman SW., 1998. Antifungal therapy during pregnancy. Clin. Infect. Dis., 27, 1151-1160.
• Leyden J., 1998. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J. Am. Acad. Dermatol., 38, 42-47.
• Maldonado RA., Molina J., Payares G., Urbina JA., 1993. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob. Agents. Chemother., 37, 1353-1359.
• Mesaik MA., Khan KM., Rahat S., Choudhary MI., Murad S., Abdullah NR., Ahmad A., Siddiqui RA., 2005. Immunomodulatory properties of synthetic imidazolone derivatives. Lett. Drug. Des. Discov., 2(6), 490-496.
• Moore KL., Persaud TVN., Torchia MG., 2008. The developing human: clinically oriented embryology. 8th ed. 458-484, Saunders/Elsevier., Philadelphia.
• Moudgal W., Sobel JD., 2003. Antifungal drugs in pregnancy: a review. Expert. Opin. Drug. Saf., 2(5), 475-483.
• Rubin PC., 1986. Prescribing in pregnancy; General principles. Br. Med. J., 293, 1415–1417.
• Shehata HA., Nelson-Piercy C., 2000. Drugs to avoid in pregnancy. Cur. Obstet. Gynaecol., 10, 44-52.
• Suhonen R., Neuvonen PJ., 1997. The tolerability profile of terbinafine. Rev. Contemp. Pharmacother. 8, 373-386.
• van Gelder MM., van Rooij IA., Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N., 2010. Teratogenic mechanisms of medical drugs. Hum. Reprod. Update., 16(4), 378-394.